Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Epithelioid Hemangioendothelioma (EHE): early-phase trial registry
2 of 2 indexed Epithelioid Hemangioendothelioma (EHE) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Epithelioid Hemangioendothelioma (EHE): 2 US clinical trials tracked, 2 recruiting.
Epithelioid Hemangioendothelioma (EHE) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is BridGene Biosciences, running 1 of these trials.
Enrollment posture brief
Registry condition epithelioid-hemangioendothelioma-ehe
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Epithelioid Hemangioendothelioma (EHE) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Epithelioid Hemangioendothelioma (EHE) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Epithelioid Hemangioendothelioma (EHE) is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences
NCT06452160
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
Sarcoma Alliance for Research through Collaboration
NCT07104331
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Epithelioid Hemangioendothelioma (EHE) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Epithelioid Hemangioendothelioma (EHE) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Epithelioid Hemangioendothelioma (EHE) page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Epithelioid Hemangioendothelioma (EHE) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- BridGene Biosciences sponsors the most Epithelioid Hemangioendothelioma (EHE) trials on record, review their full trial history before evaluating a specific study. See BridGene Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epithelioid Hemangioendothelioma (EHE) condition card totals 2 registered trials; most-linked intervention BGC515; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.